Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common treatable chronic autoimmune neuropathy. Multiple diagnostic criteria have been established, with the primary goal of identifying neurophysiologic hallmarks of acquired demyelination. Treatment modalities have expanded to include numerous immunomodulatory therapies, although the best evidence continues to be for corticosteroids, plasma exchange, and intravenous immunoglobulin (IVIg). This review describes the pathology, epidemiology, pathogenesis, diagnosis, and treatment of CIDP.
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Albumins / metabolism
-
Anti-Inflammatory Agents / therapeutic use
-
Electrodiagnosis
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use
-
Immunosuppressive Agents / therapeutic use
-
Peripheral Nerves / pathology
-
Plasma Exchange
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / cerebrospinal fluid
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / diagnosis
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / pathology
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / therapy*
-
Stem Cell Transplantation
Substances
-
Adrenal Cortex Hormones
-
Albumins
-
Anti-Inflammatory Agents
-
Immunoglobulins, Intravenous
-
Immunosuppressive Agents